drugset / Trial / NCT06773091

A Phase I Study of NK042 Cell Injection in Advanced Solid Tumors

NCT06773091

Phase 1 Recruiting 76 enrolled Shanghai NK Cell Technology Co., LTD
NaSingle-groupOpen-labelTreatment

Summary

This is a single-arm, open-label, multi-center phase 1 clinical study designed to evaluate the safety and preliminary efficacy of NK042 cell injection in patients with advanced solid tumors.

Timeline

Start
2025-02-07
Primary completion
2026-12
Completion
2027-06

Drugs

EvaluationDrugModalityDoseRoute
Subject NK042 Cell therapy
Background Cyclophosphamide Other / unclassified
Background Fludarabine Small molecule

Indications